WASHINGTON, DC USA (UroToday.com) - A fish sandwich rather than a well-cooked hamburger might decrease the risk of advanced prostate cancer according to this report!
This presentation linked meat and its resultant mutagens with advanced prostate cancer risk. It’s known that dietary consumption of various meats is associated with the development of prostate cancer. This presumably occurs through the release of carcinogenic heterocyclic amines and polyaromatic hydrocarbons when cooking or grilling meat at high temperatures. The researchers examined the consumption of various meat types, meat doneness and related meat mutagens in the development of advanced prostate cancer. They performed a nested case control study involving 506 aggressive incident prostate cancer cases and 506 controls, recruited from major medical institutions in Cleveland, Ohio, between 2001 and 2004. All subjects were given a self-administered food frequency questionnaire to provide information on meat consumption, methods of preparation and meat doneness level. They estimated odds ratios and 95% confidence intervals for risk of advanced prostate cancer through multivariate logistic regression.
When looking at various meat types, they found that BBQ hamburgers had an increased risk of advanced prostate cancer (OR = 1.21), while fish appeared to have a protective effect (OR=0.85). With respect to meat mutagens they found an increased risk with 2-amino-3,8-Dimethylimidazo-[4,5-f]Quinolaxine, when comparing the forth quartile intake with the first (OR-1.79), however this association was not seen with 2-amino-1-methyl-6-phenylimidazo-[4,5-B]Pyridine or Benzoapyrene. With respect to meat doneness, well done or very well done meat had an increased risk of advanced prostate cancer compared to rare or medium cooked meat for both red meat and fish.
Presented by John Witte, et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA
Reported for UroToday by Christopher P. Evans, MD, FACS, Professor and Chairman, Department of Urology, University of California, Davis, School of Medicine.